Tower slashes its FY23 NPAT guidance
Nick Sundich, May 8, 2023
Tower (ASX:TWR) is another insurer that has been feeling the pinch from catastrophic weather events. The company has been hit by claims from Cyclone Gabrielle as well as two further cyclones that have hit Vanuatu.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
Tower hit with claims
Tower was hit with over 3,000 claims from Cyclone Gabrielle and anticipates a $55-$75m cost when all is said and done. A further 5,550 claims have come in from the Auckland and Upper North Island Weather event, leading to a $195-$225m cost. Vanuatu’s cyclones have led to another 250 claims with a $10m net financial impact after proportional reinsurance.
In all instances, costs above $11.9m will be covered by Tower’s reinsurance for catastrophic events, which provides up to $889m of catastrophe cover.
FY23 NPAT guidance slashed
Tower previously guided to a $18-$23m NPAT for FY23 – the 12 months to September 30, 2023. But given these events, this guidance was slashed. The company is now expecting $8m-$13m for the full year and a loss for H1 of around $3m.
The company told shareholders it would take a number of steps to minimise future losses, including that it wouldn’t pay an interim dividend and has increased its large events allowance from $40m-$50m. Shares fell by nearly 10% this morning.
Tower (ASX:TWR) share price chart, log scale (Source: TradingView)
Some good news was that it upgraded its gross written premium (GWP) growth from 10-15% to 15-20%, as more people seek protection. But whilst this is a blessing for now, in the form of short-term revenues, it could be a curse down the track if catastrophic weather events continue in the South Pacific.
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
There’s no credit card needed – the trial expires automatically.
Blog Categories
Get Our Top 5 ASX Stocks for FY25
Recent Posts
Can Gold Hit $4,000 in 2025? These 5 ASX Stocks Could Soar if It Does
In our view, the question isn’t just whether gold can hit $4,000 an ounce in 2025; it’s about what happens…
Qantas Board Shake-Up: Is Investor Pressure Finally Taking Effect?
Qantas Airways, Australia’s flagship airline, has long been a symbol of national pride, maintaining a central position in the country’s…
Orthocell (ASX:OCC): All systems go for a US market roll out of its flagship Remplir nerve repair product
Orthocell (ASX:OCC) is the latest ASX biotech to obtain FDA approval. Its nerve repair product Remplir was already approved in…